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1. Introduction 
It is generally recognized that the liver is the 
major gluconeogenic tissue concerned with the 
regulation of glycemia because of the relative organ 
size as compared to that of the kidney cortex. In fact, 
glucose formed by the kidneys should provide only 
a small fraction of the blood glucose under normal 
physiological conditions, considering the renal 
removal of lactate, the main gluconeogenic precursor 
[1] . However, Owen et al. have reported that renal 
glucose production after prolonged fasting in obese 
patients approached that of the liver, which is 
decreased in these conditions [2]. On the other hand, 
Niederland et al. showed that kidneys of partially 
hepatectomized rats synthetized more glucose both 
in vitro and in vivo than the sham-operated animals 
[3] and Jones et al. reported a significant increase 
in net renal glucose production in fasted anesthetized 
dogs in which liver gluconeogenesis was inhibited 
by ethanol administration [4]. 
In previous work from this laboratory it has been 
reported that a stimulation of rat kidney phosphoenol- 
pyruvate carboxykinase activity in experimental liver 
disease induced by galactosamine when hepatic 
gluconeogenesis was severely impaired. In these 
conditions, the rise in renal phosphoenolpyruvate 
carboxykinase activity was accompanied by a slight 
but significant increase in renal gluconeogenic 
ability [5] . 
Taking these findings altogether it could be 
assumed that kidneys play an important role in 
glucose homeostasis when liver functional capacity 
diminishes. In this context we have undertaken the 
North-Holland Publishing Company - Amsterdam 
study of the renal gluconeogenic response to the 
selective inhibition of liver gluconeogenesis in order 
to avoid the generalized cellular damage which 
occurs during galactosamine treatment. 
2. Experimental 
Female rats of the Wistar strain weighing 150-200 g 
were used. 5-methoxy indole-Zcarboxylic acid (50 
and 200 mg/kg body weight) was administered as a 
neutral solution 3 h before killing. Triamcinolone 
acetonide (2.5 mg per rat) was injected 3 h before 
killing. Actinomycin D (125 E.cg/kg body weight) was 
administered 3.5 h before killing and cycloheximide 
(1 mg per rat) was injected 5 h and 2.5 h before 
killing. All the agents were intraperitoneally injected 
and were substituted by saline solution in the 
controls. The rats were killed by cervical dislocation. 
Liver gluconeogenic capacity was measured by 
perfusion with 10 mM L-lactate. The perfusion 
method has been described by Hems et al. [6]. 
The perfusate consisted of Krebs-Henseleit 
physiological saline [7] , bovine serum albumin 
powder fraction V and washed human red cells 
stored 30 days at 4°C in citrate dextrose anticoa- 
gulant solution. Glucose production by renal cortical 
slices was estimated according to Krebs et al. [8] by 
incubating the washed cells in saline medium to 
which the substrate has been added in a 10 mM 
concentration, at 40°C for 1 h, with O2 t CO2 
(95:s) as the gas phase. Glucose was determined by 
the glucose oxidase method [8,9]. 
Phosphoenolpyruvate carboxykinase activity was 
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measured spectrophotometrically in the direction of 
oxaloacetate synthesis in the presence of an excess of 
malate dehydrogenase at 3O”C, as described previously 
[lo] _ Protein was determined by the method of 
Lowry et al. [l l] , with bovine serum albumin as 
standard. 
Lactate dehydrogenase was measured by the 
method of Bergmeyer et al. [ 121. Glucose 6-phosphatase 
was determined as described by Harper [ 131 and 
fructose diphosphatase as described by Pontremoli 
et al. [ 141, by using 0.04 M glycine buffer, pH 9.4. 
3. Results and discussion 
Among the several inhibitors of liver gluconeo- 
genesis which have been extensively studied [ 151 we 
have tested the effect of 5methoxy indole-2-carboxy- 
lit acid (MICA) on rat kidney cortex gluconeogenesis 
in vitro, since it is known that this compound, which 
inhibits gluconeogenesis mainly by blocking 
mitochondrial utilization of pyruvate, has little or 
no effect on kidney mitochondria [ 16). As expected, 
the addition of MICA to the incubation medium 
produced only a slight inhibition of cortical gluconeo- 
genesis both in well fed and starved rats whereas the 
same concentrations of the inhibitor strongly 
decreased liver gluconeogenesis when added to the 
perfusion medium in starved rats (table 1). 
It seemed then that MICA was, at least to a 
certain extent, a selective inhibitor of liver gluconeo- 
genesis unlike quinolinic acid or pent-4-enoic acid, 
which were known to be powerful agents in also 
preventing kidney gluconeogenesis as shown by 
Kalhr and Schoolwerth [17] and by Senior and 
Sherratt [ 181 respectively. Consequently we have 
studied the effect of MICA administration on liver 
and kidney gluconeogenesis. 
The livers from 48 h starved rats treated with 
MICA produced about half the amount of 
glucose than controls when perfused with 10 mM 
lactate, the differences regarding the doses of the 
inhibitor being small (table 2). On the contrary, the 
production of glucose by kidney cortical slices 
from treated animals was significantly higher than 
controls both in well fed and in starved rats when the 
gluconeogenic substrates were lactate, pyruvate or 
glutamine (table 3). On the other hand, there were 
no significant differences when fructose was used 
as carbon precursor. 
The stimulation of kidney production of 
glucose as a consequence of MICA administration 
sharply contrasts with the results obtained by 
Senior and Sherrat using pent-4-enoic acid as 
gluconeogenic inhibitor. In this case the renal 
gluconeogenic ability was also reduced after the 
administration of this compound [ 181. It provides 
further support to the hypothesis that MICA acts 
in vivo as a rather selective inhibitor of liver 
gluconeogenesis. 
It is interesting to point out the higher stimulation 
of kidney gluconeogenic ability which takes place 
in well fed animals. This finding seems to suggest 
that a similar mechanism would account for the 
stimulation of gluconeogenesis in starvation and in 
the conditions created by the treatment with MICA. 
On the other hand, the lack of effect of MICA 
administration on kidney gluconeogenesis when 
Table 1 
Effect of MICA on rat liver and kidney cortex gluconeogenic ability in vitro 
Well fed rats 48 h starved rats 
__~__ ___ 
Kidney Kidney Liver 
Control 113.2 + 2.1 (17) 235.4 f 4.1 (5) 294.4 f 25.2 (6) 
0.2 mM MICA 93.6 f 4.4 (7) 208.7 f 4.2 (5) 129.1 + 6.2 (7) 
0.8 mM MICA 90.1 + 4.1 (7) 177.9 + 3.1 (5) -4.0 f 6.2 (3) 
Gluconeogenesis ability is expressed in pmoles of glucose produced per h per g tissue 
dry wt. from 10 mM lactate. The results are given as means + S.E.M., with the number 
of observations in parentheses. Experimental details are given in the text. 
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Table 2 
Effect of MICA administration on gluconeogenic 
ability in perfused liver from 48 h starved rats 
Control 396.0 ? 26.0 (4) 
MICA (SO mg/Kg) 221.6 * 8.5 (8) 
MICA (200 mg/Kg) 198.7 * 6.0 (7) 
Gluconeogenic ability is expressed in rmoles of glucose 
produced per h per g liver dry wt. from 10 mM lactate. The 
results are given as means f S.E.M., with the number of 
observations in parentheses. Experimental details are given 
in the text. .I 
fructose was the carbon precursor suggested to us 
that the primary factor responsible for the 
stimulation of glucose production was the activation 
of phosphoenolpyruvate carboxykinase, in a similar 
way than in rats treated with galactosamine [5]. 
Actually, as shown in table 4, among the enzyme 
activities tested in kidney cortex after MICA 
administration only phosphoenolpyruvate 
carboxykinase exhibited a significant increase. 
This effect was higher in fed animals than in starved 
ones in good agreement with the results regarding 
gluconeogenic ability (table 3). 
The rise in the activity of renal phosphoenol- 
pyruvate carboxykinase promoted by MICA seems 
to be due to de novo synthesis of the enzyme since 
this effect was fully counteracted by treatment 
with actinomycin D or cycloheximide (table 5), 
antibiotics which are known to inhibit protein 
synthesis [19,20] . The doses used were able to 
overcome the well known induction of phosphoenol- 
pyruvate carboxykinase by glucocorticoids [21-231. 
The results described in this paper are closely 
related to those obtained in rats treated with 
galactosamine [5] although the inhibition of liver 
gluconeogenesis is quite different in both situations. 
Thus, in rats with liver damage induced by galacto- 
samine all the key gluconeogenic enzymes are 
decreased in their activities, specially phosphoenol- 
pyruvate carboxykinase [24,25]. However, none of 
the enzymes tested in the livers of the rats treated 
with MICA (glucose 6-phosphatase, fructose 
diphosphatase, phosphoenolpyruvate carboxykinase 
and lactate dehydrogenase) showed significant 
differences to the controls both in fed and starved 
animals (results not detailed in the text). Hence, if 
one assumes that a similar mechanism would 
account for the induction of renal phosphoenol- 
pyruvate carboxykinase activity and gluconeogenic 
ability in both situations, the impairment: of liver 
gluconeogenesis hould be the common starting 
factor involved. The nature of this mechanism and 
the in vivo significance of the adaptative metabolic 
response of the kidney to the experimental 
impairment of liver gluconeogenesis are at present 
under investigation. 
Table 3 
Effect of MICA administration on rat kidney cortex gluconeogenic ability 
Experimental 
conditions Control MICA (50 me/Kg) MICA (200 mg/Kg) 
Well fed rats 
Pyruvate 
L-lactate 
Glutamine 
Fructose 
48 h starved rats 
Pyruvate 
L-lactate 
Glutamine 
Fructose 
219.4 * 6.6 (9) 
110.5 f 1.9 (17) 
115.4 + 2.5 (7) 
456.5 f 31.8 (4) 
261.1 t 8.9 (7) 
218.8 + 3.6 (10) 
155.5 r 2.1 (8) 
506.3 f 2.7 (3) 
305.8 * 6.5 (9) 
156.4 f 5.9 (8) 
160.6 * 1.7 (3) 
447.5 c 9.8 (4) 
300.4 f 12.9 (9) 
252.2 f 2.8 (8) 
184.3 + 6.3 (3) 
511.5 + 4.7 (6) 
320.6 + 
189.9 * 
175.5 * 
460.3 + 
11.3 (4) 
5.1 (7) 
4.3 (8) 
16.1 (9) 
321.5 + 
261.2 f 
195.6 f 
508.7 + 
1.9 (4) 
3.5 (4) 
6.8 (3) 
2.1 (4) 
Gluconeogenic ability is expressed in rmoles of glucose produced per h per g kidney cortex 
dry wt. The results are given as means + S.E.M., with the number of observations in parentheses. 
Experimental details are given in the text. 
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Table 4 
Effect of MICA administration on lactate dehydrogenase, phosphoenolpyruvate carboxykinase, fructose 
diphosphatase and glucose 6-phosphatase activities in rat kidney cortex 
Experimental 
conditions Control MICA 50 mg/Kg MICA 200 mg/Kg 
Well fed rats 
Lactate dchydrogenase 3.04 f 0.332 (7) 2.75 f 0.28 (10) 3.64 * 0.30 (6) 
Phosphoenolpyruvate 
carboxykinase 34.08 f 1.99 (9) 62.24 * 3.28 (6) 66.34 f 2.27 (5) 
Fructose diphosphatase 156.90 f 7.02 (10) 150.36 f 10.00 (11) 161.66 + 7.17 (6) 
Glucose 6-phosphatase 16.92 _+ 1.99 (7) 18.22 + 1.01 (7) 18.84 t 2.39 (6) 
48 h starved rats 
Lactate dehydrogenase 4.63 * 1.08 (4) 4.87 t 0.48 (3) 4.30 + 0.63 (8) 
Phosphoenolpyruvate 
carboxykinase 79.28 f 3.97 (7) 94.89 f 3.22 (5) 95.91 + 3.33 (6) 
Fructose diphosphatase 186.00 * 19.28 (3) 193.66 f 6.35 (3) 162.80 + 13.92 (5) 
Glucose 6-phosphatase 19.65 * 1.69 (7) 20.26 + 2.07 (5) 18.33 + 0.96 (5) 
.-___ 
Lactate dehydrogenase activity is expressed in pmoles of pyruvate transformed/min per mg of protein. 
Phosphoenolpyruvate carboxykinase and fructose diphosphatase activities are expressed in nmoles of 
substrate transformed/min per mg of protein. Glucose 6-phosphatase activity is expressed in nmoles of 
substrate transformed/min per g tissue wet wt. The results are given as means f S.E.M., with the number of 
observations in parentheses. Experimental details are given in the text. 
Table 5 
Effect of actinomycin D acid cycloheximide on the stimulation 
of renal phosphoenolpyruvate carboxykinase activity in rats 
treated with MICA 
Experimental 
conditions Actinomycin D Cycloheximide 
Control 33.44 f 2.39 (6) 32.16 + 1.67 (6) 
Antibiotic 32.51 + 2.32 (6) 32.89 + 1.99 (6) 
Triamcinolone 66.59 + 2.77 (7) 64.4 f 2.47 (6) 
MICA (50 mg/Kg) 65.58 f 2.24 (7) 64.92 * 2.18 (7) 
MICA + Antibiotic 31.30 f 2.75 (6) 33.42 +_ 2.41 (7) 
Triamc. + Antibiotic 35.26 +_ 2.02 (7) 31.08 f 1.22 (7) 
_ 
Phosphoenolpyruvate carboxykinase activity is expressed in nmoles of 
oxalacetate formed at 30°C per min per mg of protein. The results are 
given as means f S.E.M., with the number of observations in parentheses. 
Experimental details are given in the text. 
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